Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Longevity Economy strategy - June 2021

  • 02 August 2021 (7 min read)

The FDA approves Aduhelm, the first drug that could tackle the underlying cause of Alzheimer

  • Fitness apparel sales continue to impress as COVID-19 restrictions ease
  • Positive contribution from all our four themes, led by “wellness” and “treatment”
  • Focus remains on long-term changes brought about by ageing populations 

What’s happening?

Global ageing populations bring a host of opportunities, we are expected to live longer on average, how do we want to spend that extra time? But ageing populations, like all things, also bring challenges, one of which is an increasing prevalence of age-related diseases, such as Dementia. Drug development in Alzheimer’s disease has been particularly challenging and there had been no new drugs approved in the US for the last 20 years. But in June, the FDA approved Aduhelm, the first drug for Alzheimer’s that many believe tackles the underlying cause of the disease. While approval was not without controversy it shines a spotlight on a big unmet medical need and offers patients hope for the future. Increasingly the focus of many investors has moved from COVID-19 to the reopening of the global economy and the potential knock-on effects of a rebound in spending and increased employment in major economies. In some cases, the rebound in demand has taken investors by surprise, for example Nike released a set of financial results with record demand coming from the US as the World’s largest economy continues to normalise. It is interesting to observe that consumers are turning to fitness apparel at record levels as pandemic restrictions continue to ease. A new research paper published in June showed that people who stayed physically active throughout their lives had significantly lower medical expenses later in life2, underlining that the consumer seeking to live longer and healthier must remain active throughout their life.

Portfolio positioning and performance

The longevity economy strategy performed in line with the broader equity market (MSCI All Country World) in June with strong performance from the wellness and treatment themes.

The wellness theme of ageing acknowledges that we must live healthier throughout our lives if we want to reach our later years in good health. Therefore, the longevity economy is about our whole life not just the end of our lives and lifelong fitness is a key aspect of this. Much like we save for our retirement throughout our working lives, keeping fit is a small regular investment in our future health. Stocks such as Nike and Lululemon are well-placed to benefit from the need for life-long physical activity.

One of the striking aspects of the pandemic has been the rapid adoption of wellness services, such as telemedicine. Companies such as Teladoc were big beneficiaries of increased demand, at this point it is unclear how much of the demand will be sticky, which is why there has been more volatility in the share prices of telemedicine companies recently. What does seem clear though is that healthcare systems need to adapt to increasing demand as populations age and telemedicine has shown itself to be a credible method of absorbing increased demand, even if that demand increase occurs rapidly, which bodes well for the long-term attractiveness of telemedicine to healthcare providers.

Living longer lives in a rapidly changing world means lifelong learning will be crucial to keep our skills up to date. The challenge of investing in the education sector is it is largely non-profit and many for-profit companies suffer from poor returns, in part due to the challenges of competing with strong brands of the non-profit institutions. We believe there are some good opportunities in this sector and we are refocusing our exposure on those stocks with stronger returns metrics.


Global markets rallied to an all-time high in June, driven by positive economic growth in multiple regions and news that in the US, President Biden’s infrastructure plan had achieved bipartisan support. However, at times economic data has been contradictory, for example the US Federal Reserve recently moved forward its expected timing for interest rate increases and inflation appears to be rising in multiple regions, which could present further problems for policymakers. Overall, we remain cautiously optimistic because COVID restrictions continue to ease which should drive a normalisation of demand and data from the UK’s recent surge in COVID cases shows lower hospitalisation rates that suggest the vaccines are working as expected.

Stepping back from macroeconomic considerations, we retain the view that high quality management teams, operating businesses with a sustainable competitive advantage and with the benefit of secular tailwinds are well-placed to navigate the current disruption. Despite the headwinds many businesses faced during the pandemic, the unshakeable conclusion on the outlook for the longevity economy is that the global population continues to age and this creates opportunities for companies that are positioned to benefit from long-term changes in consumption patterns that ageing populations will bring.

No assurance can be given that the Longevity Economy Strategy will be successful. Investors can lose some or all of their capital invested. The Longevity Economy Strategy is subject to risks including: Equity; Currency; Global Investments; Emerging markets; Investments in small capitalisation universe and Investment in specific asset classes.

Read the full article
Download article (224.01 KB)

Have our latest insights delivered straight to your inbox

Subscribe to updates.

Related Articles


Japan’s hidden tech investment potential

  • by Brad Reynolds
  • 14 June 2024 (5 min read)

Generative AI: The future of e-commerce is here

  • by AXA Investment Managers
  • 30 April 2024 (7 min read)

2024: A stand-out year for UK mid-caps?

    Not for Retail distribution

    This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs.

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. 

    Are you an IFA or other Professional Investor ?

    Are you a financial advisor, institutional, or other professional investor?

    This section is for professional investors only. You need to confirm that you have the required investment knowledge and experience to view this content. This includes understanding the risks associated with investment products, and any other required qualifications according to the rules of your jurisdiction.